AstraZeneca PLC (LON:AZN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of AstraZeneca PLC (LON:AZN) have earned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is GBX 7,542.80 ($95.45).

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a research report on Wednesday, February 19th. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. Finally, Berenberg Bank reissued a “buy” rating and set a GBX 140 ($1.77) price target on shares of AstraZeneca in a research report on Monday, January 27th.

AstraZeneca Price Performance

AstraZeneca stock opened at £117.08 ($148.17) on Monday. AstraZeneca has a 12-month low of GBX 9,670 ($122.37) and a 12-month high of £133.88 ($169.43). The stock has a market capitalization of £225.27 billion, a P/E ratio of 32.09, a P/E/G ratio of 0.86 and a beta of 0.17. The firm’s 50-day moving average is £109.99 and its two-hundred day moving average is £114.55. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.